<DOC>
	<DOCNO>NCT00516165</DOCNO>
	<brief_summary>Laboratory study show RAD001 prevent cell multiply . Consequently , study drug test medical condition excessive cell multiplication ( cancer ) need stop . The main purpose research study find high dose RAD001 give safely ( without cause severe side effect ) learn effect ( good bad ) RAD001 participant liver cancer .</brief_summary>
	<brief_title>RAD001 Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description>- Participants give supply study drug RAD001 take home . They ask take study drug every morning empty stomach give study drug diary record time/date time take RAD001 . Each 6 week period time call cycle study treatment . - We look high dose RAD001 give safely . Therefore every participant receive dose RAD001 . - Participants come clinic every week . At visit , physical examination blood test perform . - A CT MRI repeat every 6 week first 3 cycle treatment every 12 week thereafter .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Unresectable metastatic HCC . Patients must prior core biopsy confirm diagnosis HCC archive tissue available correlative study At least one measurable site disease accord RECIST criterion previously irradiate . If previous radiation teh marker lesion ( ) , must evidence progression since radiation 02 prior systemic chemotherapy biologic regimens hepatocellular carcinoma Patients prior chemoembolization history participate study chemoembolization perform 4 week ago patient must measurable disease outside prior chemoembolization field 18 year age old Minimum 4 week since major surgery completion radiation Minimum 4 week since completion prior systemic anticancer therapy ECOG performance status 02 CLIP score equal less 3 Adequate bone marrow , liver renal function outline protocol Prior treatment investigational drug within precede 4 week Chronic treatment systemic steroid another immunosuppressive agent Uncontrolled brain leptomeningeal metastasis , include patient continue require glucocorticoid brain leptomeningeal metastases Patients severe and/or uncontrolled medical condition condition could affect participation study Known history HIV seropositivity Impairment gastrointestinal function gastrointestinal disease may significantly alter absorption RAD001 Active , bleed diathesis Women pregnant breast feeding Patients receive prior treatment mTor inhibitor Patients know hypersensitivity RAD001 rapamycins excipients History noncompliance medical regimen Patients positive dipstick urine protein ( read 2+ great ) undergo 24hour urine collection protein . If patient 2g great protein/24hr , exclude study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>liver cancer</keyword>
	<keyword>RAD001</keyword>
</DOC>